Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

In lab studies, blocking expression of gene reduces invasion of deadly brain tumor cells

21.10.2003


In July 2001, scientists at Cedars-Sinai’s Maxine Dunitz Neurosurgical Institute published their findings that one "isoform" or variant of a specific gene was significantly upregulated in high-grade, malignant brain tumors called glioblastoma multiforme (GBM). They theorized that this increased activity might be a critical step in the development, progression and spread of these highly aggressive tumors.



Now, in laboratory experiments designed to mimic the environment of a brain tumor and its abnormal influence on surrounding normal blood vessel cells, the researchers have found that by blocking the expression of this gene, laminin-8, they were able to reduce the tumor’s ability to invade neighboring tissue. The new study supports the hypothesis that laminin-8 is involved in the spread of these malignancies, and it reinforces the possibility that a therapy may be developed to arrest the tumors by targeting the gene.

In the original study, published in Cancer Research, the scientists used "gene array" technology to rapidly and efficiently analyze the expression of 11,004 genes in samples of low-grade tumors; high-grade tumors; brain tissue that had been located in close proximity to high-grade tumors; and unrelated normal brain tissue.


Two genes were consistently up-regulated in all high-grade and low-grade gliomas and in tissues adjacent to GBMs, the most aggressive gliomas. One of the genes was already known to be over-expressed in gliomas. The other was the alpha-4 chain of laminin, a gene that influences the thin "basement membrane" that lies beneath the surface layer of blood vessels.

One of the alpha-4 chain-containing laminin isoforms, laminin-9, was expressed mainly in the blood vessel walls of low-grade tumors and normal brain. Laminin-8 was expressed primarily in the vessel walls of the high-grade GBMs and the tissue adjacent to these types of tumors. There were some exceptions. In those cases, it was noted that an overexpression of laminin-8 correlated with a shorter time to tumor recurrence than when there was an overexpression of laminin-9. Overexpression of laminin-8 was, therefore, identified as a predictor of glioma recurrence and a potential target of intervention strategies.

These observations were reinforced by the new study, which used short strands of genetic code (Morpholino™ antisense oligonucleotides) to block the messenger RNA (mRNA) carrying the gene’s "instructions." As a result, the gene’s "protein product," laminin-8, was not produced and the invasiveness of glioma cells was significantly reduced.

Although antisense intervention was introduced more than two decades ago, new technology has overcome many earlier limitations. Unlike its predecessors, for example, Morpholino is stable in plasma.

New-generation antisense oligos are being used in studies to find effective medications and treatments for many disorders, including viruses and cancers. By blocking a gene’s effects in a laboratory setting, they enable scientists to study the gene, its control, and the interactions between gene products.

"Antisense technology is being refined not only for drug validation and diagnostic purposes but also for the development of future treatments for patients. It may become an effective tumor therapy because it offers efficiency, specificity and ease of delivery to tumor cells," said Keith L. Black, M.D., director of Cedars-Sinai’s Maxine Dunitz Neurosurgical Institute. Dr. Black directs the medical center’s Division of Neurosurgery and the Comprehensive Brain Tumor Program and holds the Ruth and Lawrence Harvey Chair in Neuroscience.

According to Julia Y. Ljubimova, M.D., Ph.D., research scientist at the Institute, the researchers decided not to conduct the experiments using glioma cells alone because laminin-8 appears to be produced both by glioma cells and by endothelial cells. By co-culturing glioma cells and brain endothelium, they were better able to mimic the situation as it would exist in actual patient tissue. Although scientists cannot say with certainty how laminin-8 promotes the spread of gliomas, this and previous studies suggest that it reduces cell adhesion and enhances cell migration – both in glioma cells and in adjacent vascular cells – circumstances that are necessary for local tumor invasiveness.

"Antisense oligos to laminin-8 chains significantly inhibited invasion of two different glioma cell lines in vitro," said Dr. Ljubimova. "If these laboratory studies can be translated into patient therapy, antisense oligos may slow the growth and spread of aggressive gliomas. Perhaps it will be used in combination with more traditional therapies or with other genetic targeting to prolong disease-free periods and increase survival."

The study was supported by a grant from the Maxine Dunitz Neurosurgical Institute. It was conducted by scientists from the Institute, the Ophthalmology Research Laboratories at Cedars-Sinai, Osaka (Japan) University Medical Center, the Interdisciplinary Center for Clinical Research at the University of Erlangen-Nuremberg (Germany), and the Institute of Biomedicine/Anatomy at the University of Helsinki (Finland).


Cedars-Sinai is one of the largest nonprofit academic medical centers in the Western United States. For the fifth straight two-year period, it has been named Southern California’s gold standard in health care in an independent survey. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthroughs in biomedical research and superlative medical education. It ranks among the top 10 non-university hospitals in the nation for its research activities.

Sandra Van | Van Communications
Further information:
http://www.csmc.edu/

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>